STAT

Merck joins the list of drug makers agreeing to freeze or lower some prices

“It’s as clear as the drug pricing system is clear,” Dr. Walid Gellad said about vows to halt price hikes.
Source: Mel Evans/AP

As political pressure on the pharmaceutical industry builds, Merck has become the latest big drug maker to commit to halting price hikes.

In a brief , the company agreed not to increase the average net prices of its medicines by more than inflation annually, and then also dropped the wholesale — or list — price by 60 percent on its Zepatier hepatitis C treatment and lowered list prices by 10 percent

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks